Entropy Technologies LP Has $2.87 Million Stock Holdings in Biogen Inc. $BIIB

Entropy Technologies LP boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 576.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,312 shares of the biotechnology company’s stock after buying an additional 13,899 shares during the period. Entropy Technologies LP’s holdings in Biogen were worth $2,871,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BIIB. Norges Bank acquired a new position in Biogen during the fourth quarter worth $464,408,000. Boston Partners acquired a new position in Biogen during the fourth quarter worth $302,815,000. Orion Porfolio Solutions LLC raised its holdings in Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after buying an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec raised its holdings in Biogen by 718.2% during the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after buying an additional 499,676 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Biogen by 30.7% during the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after buying an additional 418,776 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the topic of several research reports. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $214.00) on shares of Biogen in a report on Friday, May 15th. Oppenheimer upped their price objective on shares of Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. The Goldman Sachs Group upped their price objective on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Barclays assumed coverage on shares of Biogen in a report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price objective on the stock. Finally, UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and increased their target price for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $217.26.

Biogen Price Performance

BIIB opened at $200.05 on Monday. The firm has a market cap of $29.54 billion, a P/E ratio of 21.46 and a beta of 0.20. The firm has a 50-day moving average of $188.73 and a 200 day moving average of $184.37. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts expect that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.